Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Venturepharm Invests in US CRO and Details Building Plans

publication date: Aug 20, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Venturepharm Laboratories Limited, based in Beijing but listed in Hong Kong as a subsidiary of Venturepharm Holdings, has become the largest shareholder of the NASDAQ listed CRO, Commonwealth Biotechnologies Inc. Venturepharm purchased 43.65% of the outstanding common shares of CBI. By completing this sale, Venturepharm follows a pattern in which China-based CROs make deals with complementary companies located in the US. More details...

Stock Symbols: (HKEX: 8225) (NSDQ: CBTE)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...